BACKGROUND: Chronic inflammation and immune dysfunction occur in human immunodeficiency virus (HIV)-infection despite stable antiretroviral therapy (ART). Red blood cell distribution width (RDW) has been shown to correlate with markers of inflammation in non-HIV conditions. The study objective was to determine associations between RDW with cellular markers of immune activation and immune dysfunction including soluble inflammatory mediators in ART treated HIV infection. METHODS: We performed a cross-sectional analysis of the Hawaii Aging with HIV-Cardiovascular study. RDW was defined as one standard deviation of RBC size divided by mean corpuscular volume multiplied by 100%. Correlations were analyzed between RDW, soluble inflammatory biomarkers and T cell activation (CD38 + HLA-DR+), senescence (CD28-CD57+), and immune exhaustion (PD-1, TIGIT, TIM-3 expression). RESULTS: Of 158 participants analyzed, median age was 50 years, duration of ART 12.6 years, virally suppressed 84.4%, and CD4 count 503 cells/mm3. Significant positive correlations were identified between RDW and soluble biomarkers including sICAM, IL-8, IL-6, SAA, TNF-α, sE-selection, fibrinogen, D-dimer, CRP, CD4/CD8 ratio, and frequency of multiple CD8 T-cell populations such as CD38 + HLA-DR + T-cells, single TIGIT+, and dual expressing of TIGIT + PD1+, TIGIT + TIM3+, and TIM3 + PD1+ CD8+ T-cell subsets (p < .05). Frequencies of CD38 + HLA-DR + CD8+ T-cells and TIGIT + CD8+ T-cells remained significant adjusting for baseline variables (p < .01). CONCLUSION: Our study revealed correlations between RDW with systemic inflammatory biomarkers and CD8+ T-cell populations related to immune activation and exhaustion in HIV-infected individuals on ART. Further studies are warranted to determine the utility of RDW as a marker of immune dysregulation in HIV.
BACKGROUND:Chronic inflammation and immune dysfunction occur in humanimmunodeficiency virus (HIV)-infection despite stable antiretroviral therapy (ART). Red blood cell distribution width (RDW) has been shown to correlate with markers of inflammation in non-HIV conditions. The study objective was to determine associations between RDW with cellular markers of immune activation and immune dysfunction including soluble inflammatory mediators in ART treated HIV infection. METHODS: We performed a cross-sectional analysis of the Hawaii Aging with HIV-Cardiovascular study. RDW was defined as one standard deviation of RBC size divided by mean corpuscular volume multiplied by 100%. Correlations were analyzed between RDW, soluble inflammatory biomarkers and T cell activation (CD38 + HLA-DR+), senescence (CD28-CD57+), and immune exhaustion (PD-1, TIGIT, TIM-3 expression). RESULTS: Of 158 participants analyzed, median age was 50 years, duration of ART 12.6 years, virally suppressed 84.4%, and CD4 count 503 cells/mm3. Significant positive correlations were identified between RDW and soluble biomarkers including sICAM, IL-8, IL-6, SAA, TNF-α, sE-selection, fibrinogen, D-dimer, CRP, CD4/CD8 ratio, and frequency of multiple CD8 T-cell populations such as CD38 + HLA-DR + T-cells, single TIGIT+, and dual expressing of TIGIT + PD1+, TIGIT + TIM3+, and TIM3 + PD1+ CD8+ T-cell subsets (p < .05). Frequencies of CD38 + HLA-DR + CD8+ T-cells and TIGIT + CD8+ T-cells remained significant adjusting for baseline variables (p < .01). CONCLUSION: Our study revealed correlations between RDW with systemic inflammatory biomarkers and CD8+ T-cell populations related to immune activation and exhaustion in HIV-infected individuals on ART. Further studies are warranted to determine the utility of RDW as a marker of immune dysregulation in HIV.
Entities:
Keywords:
T cell dysregulation; human immunodeficiency virus; immune activation and exhaustion; immune checkpoint; inflammatory biomarker; red blood cell distribution width
Authors: Cecilia M Shikuma; Jason D Barbour; Lishomwa C Ndhlovu; Sheila M Keating; Philip J Norris; Matthew Budoff; Nisha Parikh; Todd Seto; Louie Mar A Gangcuangco; Debra Ogata-Arakaki; Dominic Chow Journal: AIDS Res Hum Retroviruses Date: 2013-09-21 Impact factor: 2.205
Authors: Glen M Chew; Tsuyoshi Fujita; Gabriela M Webb; Benjamin J Burwitz; Helen L Wu; Jason S Reed; Katherine B Hammond; Kiera L Clayton; Naoto Ishii; Mohamed Abdel-Mohsen; Teri Liegler; Brooks I Mitchell; Frederick M Hecht; Mario Ostrowski; Cecilia M Shikuma; Scott G Hansen; Mark Maurer; Alan J Korman; Steven G Deeks; Jonah B Sacha; Lishomwa C Ndhlovu Journal: PLoS Pathog Date: 2016-01-07 Impact factor: 6.823
Authors: Ingrid Elisia; Vivian Lam; Brandon Cho; Mariah Hay; Michael Yu Li; Jordanna Kapeluto; Tom Elliott; David Harris; Luke Bu; William Jia; Hilary Leung; William Mohn; Gerald Krystal Journal: PLoS One Date: 2020-02-06 Impact factor: 3.240
Authors: Eva Poveda; Andrés Tabernilla; Wendy Fitzgerald; Ángel Salgado-Barreira; Marta Grandal; Alexandre Pérez; Ana Mariño; Hortensia Álvarez; Nieves Valcarce; Juan González-García; José Ignacio Bernardino; Félix Gutierrez; Hisashi Fujioka; Manuel Crespo; Ezequiel Ruiz-Mateos; Leonid Margolis; Michael M Lederman; Michael L Freeman Journal: J Infect Dis Date: 2022-03-15 Impact factor: 7.759